SCHEDULE 13G 0001792691 XXXXXXXX LIVE Common Stock, par value $0.001 per share 06/26/2024 0001175151 Cytosorbents Corp 23283X206 305 COLLEGE ROAD EAST PRINCETON NJ 08540 Rule 13d-1(d) Avenue Venture Opportunities Fund, L.P. DE 0.00 0.00 0.00 0.00 1126582.00 N 1.7 OO (1) Aggregate amount owned includes 632,911 shares of common stock issuable upon conversion of a loan to Issuer in the principal amount of $600,000 and 493,671 shares of common stock issuable upon exercise of warrants outstanding. Such loan is convertible at any time at lender's option at a per share conversion price of $0.948. (2) Percent of class is based on. 62,610,376 fully diluted shares of Common Stock of Cytosorbents Corporation (the "Issuer") outstanding as of May 13, 2025. Avenue Venture Opportunities Fund II, L.P. DE 0.00 0.00 0.00 0.00 2628691.00 N 4.0 OO (1) Aggregate amount owned includes 1,476,793 shares of common stock issuable upon conversion of a loan to Issuer in the principal amount of $1.4 million and 1,151,898 shares of common stock issuable upon exercise of warrants outstanding. Such loan is convertible at any time at lender's option at a per share conversion price of $0.948. (2) Percent of class is based on 62,610,376 fully diluted shares of Common Stock of Issuer outstanding as of May 13, 2025. Avenue Capital Management II, L.P. DE 3755273.00 0.00 3755273.00 0.00 3755273.00 N 5.7 IA (1) Avenue Capital Management II, L.P. is a registered investment adviser and is the manager ("Manager") of each of Avenue Venture Opportunities Fund, L.P. ("Fund") and Avenue Venture Opportunities Fund II, L.P. ("Fund II", and with Fund, the "Funds"). The general partner of each of Fund and Fund II has delegated all management authority to Manager and therefore, Manager has sole voting and dispositive power over all securities of Issuer held by the Funds but disclaims beneficial ownership thereof except to the extent of its pecuniary interest, if any, therein. (2) Percent of class is based on 62,610,376 fully diluted shares of Common Stock of Issuer outstanding as of May 13, 2025. Avenue Venture Opportunities Partners, LLC DE 0.00 0.00 0.00 0.00 1126582.00 N 1.7 OO (1) Avenue Venture Opportunities Partners, LLC ("AVOP") is the general partner of Fund and has delegated voting and dispositive power over securities held by Fund to Manager. AVOP disclaims beneficial ownership of securities held by Fund, except to the extent of its pecuniary interest, if any, therein. (2) Percent of class is based on 62,610,376 fully diluted shares of Common Stock of Issuer outstanding as of May 13, 2025. Avenue Venture Opportunities Partners II, LLC DE 0.00 0.00 0.00 0.00 2628691.00 N 4.0 OO (1) Avenue Venture Opportunities Partners II, LLC ("AVOPII") is the general partner of Fund II and has delegated voting and dispositive power over securities held by Fund II to Manager. AVOPII disclaims beneficial ownership of securities held by Fund II, except to the extent of its pecuniary interest, if any, therein. (2) Percent of class is based on 62,610,376 fully diluted shares of Common Stock of Issuer outstanding as of May 13, 2025. GL Venture Opportunities Partners, LLC DE 0.00 0.00 0.00 0.00 1126582.00 N 1.7 OO (1) GL Venture Opportunities Partners, LLC ("GLVOP") is the managing member of AVOP, the general partner of Fund. GLVOP has no voting or dispositive power over securities held by Fund and disclaims beneficial ownership of securities held by Fund, except to the extent of its pecuniary interest, if any, therein. (2) Percent of class is based on 62,610,376 fully diluted shares of Common Stock of Issuer outstanding as of May 13, 2025. GL Venture Opportunities Partners II, LLC DE 0.00 0.00 0.00 0.00 2628691.00 N 4.0 OO (1) GL Venture Opportunities Partners II, LLC ("GLVOPII") is the managing member of AVOPII, the general partner of Fund II. GLVOPII has no voting or dispositive power over securities held by Fund II and disclaims beneficial ownership of securities held by Fund II, except to the extent of its pecuniary interest, if any, therein. (2) Percent of class is based on 62,610,376 fully diluted shares of Common Stock of Issuer outstanding as of May 13, 2025. Marc Lasry X1 0.00 0.00 0.00 0.00 3755273.00 N 5.7 IN (1) Marc Lasry is the beneficial owner of GLVOP and GLVOPII and therefore, is the ultimate beneficial owner of the Funds. Mr. Lasry does not have voting or dispositive power over securities held by the Funds. (2) Percent of class is based on 62,610,376 fully diluted shares of Common Stock of Issuer outstanding as of May 13, 2025. Cytosorbents Corp 305 College Road East, Princeton, New Jersey 08540 Avenue Venture Opportunities Fund, L.P., Avenue Venture Opportunities Fund II, L.P., Avenue Capital Management II, L.P., Avenue Venture Opportunities Partners, LLC, Avenue Venture Opportunities Partners II, LLC, GL Venture Opportunities Partners, LLC, GL Venture Opportunities Partners II, LLC, Marc Lasry Avenue Capital Group 11 West 42nd Street, 9th Floor, New York, New York 10036 Avenue Venture Opportunities Fund, L.P., Avenue Venture Opportunities Fund II, L.P., Avenue Capital Management II, L.P., Avenue Venture Opportunities Partners, LLC, Avenue Venture Opportunities Partners II, LLC, GL Venture Opportunities Partners, LLC, and GL Venture Opportunities Partners II, LLC are organized under the laws of the State of Delaware. Marc Lasry is a U.S. citizen. Y The information required by this Item 4(a) is set forth in Row (9) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The information required by this Item 4(b) is set forth in Row (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. % The information required by this Item 4(c)(i) is set forth in Row (5) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The information required by this Item 4(c)(ii) is set forth in Row (6) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The information required by this Item 4(c)(iii) is set forth in Row (7) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The information required by this Item 4(c)(iv) is set forth in Row (8) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99.1: Power of Attorney dated January 28, 2019 (filed as Exhibit 99.1 to Schedule 13G on October 3, 2024). https://www.sec.gov/Archives/edgar/data/1792691/000182912624006629/beyondair_ex99-1.htm Exhibit 99.2: Joint Filing Agreement (Filed Herewith). Avenue Venture Opportunities Fund, L.P. /s/ Andrew Schinder 05/28/2025 Avenue Venture Opportunities Fund II, L.P. /s/ Andrew Schinder 05/28/2025 Avenue Capital Management II, L.P. /s/ Andrew Schinder 05/28/2025 Avenue Venture Opportunities Partners, LLC /s/ Andrew Schinder 05/28/2025 Avenue Venture Opportunities Partners II, LLC /s/ Andrew Schinder 05/28/2025 GL Venture Opportunities Partners, LLC /s/ Andrew Schinder 05/28/2025 GL Venture Opportunities Partners II, LLC /s/ Andrew Schinder 05/28/2025 Marc Lasry /s/ Andrew Schinder 05/28/2025